Status:
COMPLETED
Understanding Magnetic Resonance Imaging in Multiple Sclerosis
Lead Sponsor:
Universitätsklinikum Hamburg-Eppendorf
Collaborating Sponsors:
Sanofi
Conditions:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Magnetic resonance imaging (MRI) results play a major role in the lives of people with multiple sclerosis (pwMS). Even though MRI is used for diagnosis, prognosis and therapy control, pwMS' knowledge ...
Detailed Description
For the randomized controlled trial (RCT), n=120 consecutive patients of 4 centers, for whom a brain (or brain and spine) MRI scan is planned within the next 6 months, will be invited to participate i...
Eligibility Criteria
Inclusion
- 18 years 65 years
- MRI within 6 weeks to 6 months
- internet access AND
- diagnosis of relapsing-remitting MS (RRMS) according to the McDonald criteria (Thompson et al., 2018), \<10 years disease duration + active disease course (i.e. therapy change or new T2 lesion within the previous year) OR
- clinically isolated syndrome (CIS) (with at least one MS-typical T2 lesion)
Exclusion
- diagnosis of secondary-progressive MS
- diagnosis of primary-progressive MS
- diagnosis or suspected central nervous system disease other than MS
- severe cognitive deficit
- major psychiatric illness
- patients who are related to medical personnel
Key Trial Info
Start Date :
March 15 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT03872583
Start Date
March 15 2019
End Date
December 1 2022
Last Update
January 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Medical Centre Hamburg-Eppendorf
Hamburg, Germany, 20246